

Press release
March 26, 2025

Curasight announces new date of the Annual General Meeting and an updated financial calendar 2025

Copenhagen, Denmark, March 26, 2025 – Curasight A/S (“Curasight” or the “Company” – TICKER: CURAS) announces that the Company’s Annual General Meeting will be held on May 28, 2025 and an updated financial calendar for rest of 2025.

The Annual General Meeting of Curasight is planned to be held on May 28, 2025. Consequently, the financial calendar and information on the date of the Annual General Meeting set out in the Annual Report for the financial year 2024 are updated accordingly.

Curasight has thus scheduled the following dates for the remainder of 2025:

Deadline for submission of shareholder proposals to Annual General Meeting - May 5, 2025

Annual Report 2024 - May 13, 2025

Annual General Meeting - May 28, 2025

Interim Report Q1 2025 - May 28, 2025

Interim Report First Half 2025 - August 28, 2025

Interim Report Q3 2025 - November 27, 2025

For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO
Phone: +45 22 83 01 60
E-mail: uk@curasight.com
www.curasight.com

Curasight is a clinical development company based in Copenhagen, Denmark. The Company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging (uTRACE®) and Radioligand Therapy (uTREAT®) Theranostic Platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology is expected to improve diagnosis and provide more gentle and efficient treatment of multiple cancer types.